review article | Q7318358 |
scholarly article | Q13442814 |
P356 | DOI | 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7 |
P698 | PubMed publication ID | 10825229 |
P2093 | author name string | Cress WD | |
Seto E | |||
P2860 | cites work | Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation | Q22003769 |
Identification and characterization of a family of mammalian methyl-CpG binding proteins | Q22003967 | ||
Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex | Q22004265 | ||
CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex | Q22008610 | ||
The 400 kDa subunit of the PCAF histone acetylase complex belongs to the ATM superfamily | Q22008654 | ||
Role of DNA 5-methylcytosine transferase in cell transformation by fos | Q22008665 | ||
Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor | Q22008813 | ||
MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1 | Q22009114 | ||
Three proteins define a class of human histone deacetylases related to yeast Hda1p | Q22009464 | ||
Crystal structure of the nucleosome core particle at 2.8 A resolution | Q22122355 | ||
Dual retinoblastoma-binding proteins with properties related to a negative regulator of ras in yeast | Q24304570 | ||
A retinoblastoma-binding protein related to a negative regulator of Ras in yeast | Q24311553 | ||
Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor | Q24311650 | ||
SAP30, a novel protein conserved between human and yeast, is a component of a histone deacetylase complex | Q24311791 | ||
Synergistic activation of transcription by CBP and p53 | Q24311979 | ||
Nucleosome assembly by a complex of CAF-1 and acetylated histones H3/H4 | Q24313176 | ||
Characterization of the CHD family of proteins | Q24317090 | ||
Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation | Q24318303 | ||
Nucleosomal DNA regulates the core-histone-binding subunit of the human Hat1 acetyltransferase | Q24320001 | ||
Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex | Q24320470 | ||
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex | Q24324026 | ||
The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins | Q24328753 | ||
A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A | Q24336667 | ||
DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts | Q24336806 | ||
ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors | Q24522848 | ||
Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes | Q24534154 | ||
Net, a negative Ras-switchable TCF, contains a second inhibition domain, the CID, that mediates repression through interactions with CtBP and de-acetylation | Q24534166 | ||
HDAC4 deacetylase associates with and represses the MEF2 transcription factor | Q24534407 | ||
Effects of short chain fatty acids on a new human colon carcinoma cell line (LIM1215). | Q24548152 | ||
The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc | Q24554343 | ||
HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor | Q24554388 | ||
RBP1 recruits both histone deacetylase-dependent and -independent repression activities to retinoblastoma family proteins | Q24554426 | ||
E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25A during keratinocyte cell cycle arrest | Q24554533 | ||
E2F-4 and E2F-5, two members of the E2F family, are expressed in the early phases of the cell cycle | Q24563485 | ||
Genetic characterization of a mammalian protein-protein interaction domain by using a yeast reverse two-hybrid system | Q24596103 | ||
The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase | Q24642494 | ||
Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3 | Q24648290 | ||
E2F-5, a new E2F family member that interacts with p130 in vivo | Q24652329 | ||
Characterization of a human RPD3 ortholog, HDAC3 | Q24670403 | ||
BRCA1 interacts with components of the histone deacetylase complex | Q24684925 | ||
Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain | Q27860534 | ||
The transcriptional coactivators p300 and CBP are histone acetyltransferases | Q27860843 | ||
HDA1 and HDA3 are components of a yeast histone deacetylase (HDA) complex | Q27933143 | ||
Repression by Ume6 involves recruitment of a complex containing Sin3 corepressor and Rpd3 histone deacetylase to target promoters | Q27936998 | ||
HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription | Q27937238 | ||
Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation | Q27937778 | ||
The major cytoplasmic histone acetyltransferase in yeast: links to chromatin replication and histone metabolism | Q27938564 | ||
The CBP co-activator is a histone acetyltransferase | Q28131758 | ||
Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation | Q28139187 | ||
RLIM inhibits functional activity of LIM homeodomain transcription factors via recruitment of the histone deacetylase complex | Q28141074 | ||
A Smad transcriptional corepressor | Q28141283 | ||
Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes | Q28141631 | ||
A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p | Q28141771 | ||
Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? | Q28142433 | ||
Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3 | Q28236241 | ||
An amino-terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3 | Q28236250 | ||
Histone deacetylase activity is required for full transcriptional repression by mSin3A | Q28238079 | ||
Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression | Q28238089 | ||
E2F-4, a new member of the E2F transcription factor family, interacts with p107 | Q28240565 | ||
E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo | Q28240575 | ||
A component of the transcriptional repressor MeCP1 shares a motif with DNA methyltransferase and HRX proteins | Q28242685 | ||
Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family | Q28252866 | ||
The adenovirus E1A-associated 130-kD protein is encoded by a member of the retinoblastoma gene family and physically interacts with cyclins A and E | Q28257000 | ||
Isolation of the Rb-related p130 through its interaction with CDK2 and cyclins | Q28257012 | ||
Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein | Q28260016 | ||
Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells | Q28261709 | ||
Retinoblastoma protein recruits histone deacetylase to repress transcription | Q28262144 | ||
Retinoblastoma protein represses transcription by recruiting a histone deacetylase | Q28262155 | ||
Role of the histone deacetylase complex in acute promyelocytic leukaemia | Q28263534 | ||
Rb interacts with histone deacetylase to repress transcription | Q28263985 | ||
Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA | Q28265233 | ||
Molecular cloning, chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma gene product-related protein | Q28272090 | ||
A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p | Q28276243 | ||
The regulation of E2F by pRB-family proteins | Q28278789 | ||
SAP30, a component of the mSin3 corepressor complex involved in N-CoR-mediated repression by specific transcription factors | Q28279441 | ||
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer | Q28285050 | ||
The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities | Q28286772 | ||
A transcriptional co-repressor that interacts with nuclear hormone receptors | Q28289864 | ||
Relief of YY1 transcriptional repression by adenovirus E1A is mediated by E1A-associated protein p300 | Q28301874 | ||
Identification of mouse histone deacetylase 1 as a growth factor-inducible gene | Q28506282 | ||
Identification of a new family of higher eukaryotic histone deacetylases. Coordinate expression of differentiation-dependent chromatin modifiers | Q28512335 | ||
Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression | Q28513708 | ||
MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin | Q28576622 | ||
Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes | Q28576708 | ||
A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression | Q28578229 | ||
A functional interaction between the histone deacetylase Rpd3 and the corepressor groucho in Drosophila development | Q28609065 | ||
Differential regulation of E2F transactivation by cyclin/cdk2 complexes | Q28612933 | ||
Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription | Q29547568 | ||
Histone acetylation and transcriptional regulatory mechanisms | Q29547707 | ||
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia | Q29616211 | ||
A multiple subunit Mi-2 histone deacetylase from Xenopus laevis cofractionates with an associated Snf2 superfamily ATPase | Q29617070 | ||
Cancer epigenetics comes of age | Q29617275 | ||
Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis | Q29619200 | ||
Cloning and characterization of the murine histone deacetylase (HDAC3). | Q30775231 | ||
Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism | Q30779195 | ||
The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth | Q33292242 | ||
E2F-1 blocks terminal differentiation and causes proliferation in transgenic megakaryocytes | Q33495156 | ||
The Mad protein family links transcriptional repression to cell differentiation | Q33671500 | ||
Histone deacetylase directs the dominant silencing of transcription in chromatin: association with MeCP2 and the Mi-2 chromodomain SWI/SNF ATPase | Q33671506 | ||
A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites | Q33706825 | ||
The nuclear matrix protein NMP-1 is the transcription factor YY1. | Q33781429 | ||
A mammalian protein with specific demethylase activity for mCpG DNA. | Q33853552 | ||
Histone acetyltransferase activity and interaction with ADA2 are critical for GCN5 function in vivo. | Q33886079 | ||
Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation | Q33888879 | ||
Ligand-induced recruitment of a histone deacetylase in the negative-feedback regulation of the thyrotropin beta gene | Q33891279 | ||
c-Myc target genes involved in cell growth, apoptosis, and metabolism | Q33956988 | ||
Histone deacetylase 1 can repress transcription by binding to Sp1. | Q33958899 | ||
A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product | Q34091691 | ||
Dietary fiber, vegetables, and colon cancer: critical review and meta-analyses of the epidemiologic evidence | Q34184872 | ||
Cell-cycle regulation of human B-myb transcription. | Q34302665 | ||
Cell cycle regulation of E2F site occupation in vivo. | Q34374974 | ||
Butyrate production from dietary fibre and protection against large bowel cancer in a rat model | Q34376463 | ||
Multiple members of the E2F transcription factor family are the products of oncogenes | Q34610790 | ||
A CBP/p300 homolog specifies multiple differentiation pathways in Caenorhabditis elegans. | Q35195830 | ||
Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. | Q35207550 | ||
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. | Q35976663 | ||
Oncogenic capacity of the E2F1 gene | Q36006249 | ||
Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. | Q36224734 | ||
Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma | Q36243414 | ||
Acetylation and modulation of erythroid Krüppel-like factor (EKLF) activity by interaction with histone acetyltransferases | Q36278311 | ||
Transformation of hematopoietic cells by the Ski oncoprotein involves repression of retinoic acid receptor signaling | Q36308232 | ||
p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells | Q36489810 | ||
Expression of dominant-negative mutant DP-1 blocks cell cycle progression in G1 | Q36560847 | ||
Human fibroblast commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent | Q36562455 | ||
In squamous cell carcinoma of the vulva, overexpression of p53 is a late event and neither p53 nor mdm2 expression is a useful marker to predict lymph node metastases | Q36620156 | ||
RPD3 encodes a second factor required to achieve maximum positive and negative transcriptional states in Saccharomyces cerevisiae | Q36744711 | ||
Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function | Q36835675 | ||
Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. | Q37550149 | ||
The retinoblastoma susceptibility gene product represses transcription when directly bound to the promoter | Q38296590 | ||
Mutations of E2F-4 trinucleotide repeats in colorectal cancer with microsatellite instability | Q38352327 | ||
A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains. | Q38352823 | ||
The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. | Q39725251 | ||
Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals | Q40023280 | ||
n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells | Q40497185 | ||
The retinoid signaling pathway: molecular and genetic analyses | Q40693606 | ||
Cell cycle targets of the DNA tumor viruses | Q40757521 | ||
Acetylation of MyoD directed by PCAF is necessary for the execution of the muscle program | Q40908837 | ||
Chicken histone deacetylase-2 controls the amount of the IgM H-chain at the steps of both transcription of its gene and alternative processing of its pre-mRNA in the DT40 cell line | Q40935773 | ||
MBP-1 physically associates with histone deacetylase for transcriptional repression | Q40942403 | ||
Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites | Q41066638 | ||
Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors | Q41110587 | ||
Polarity-specific activities of retinoic acid receptors determined by a co-repressor. | Q41284148 | ||
RB kinases and RB-binding proteins: new points of view | Q41341093 | ||
Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line | Q41393518 | ||
DNA methylation: a molecular lock | Q41441579 | ||
Transcriptional regulation during myelopoiesis | Q41589633 | ||
Retinoblastoma protein switches the E2F site from positive to negative element | Q41613404 | ||
Identification of a growth suppression domain within the retinoblastoma gene product | Q41619792 | ||
Role of the retinoblastoma protein in the pathogenesis of human cancer | Q41639462 | ||
A SAGA of histone acetylation and gene expression | Q41653844 | ||
Role of E2F in cell cycle control and cancer | Q41747104 | ||
Mechanism of active transcriptional repression by the retinoblastoma protein | Q42479902 | ||
Shared role of the pRB-related p130 and p107 proteins in limb development | Q42633203 | ||
Sodium butyrate induces NIH3T3 cells to senescence-like state and enhances promoter activity of p21WAF/CIP1 in p53-independent manner | Q42797574 | ||
Two E2F sites control growth-regulated and cell cycle-regulated transcription of the Htf9-a/RanBP1 gene through functionally distinct mechanisms. | Q42817452 | ||
A novel tetracyclic peptide, trapoxin, induces phenotypic change from transformed to normal in sis-oncogene-transformed NIH3T3 cells | Q42820485 | ||
Regulation of activity of the transcription factor GATA-1 by acetylation | Q42823439 | ||
The thyroid hormone receptor binds with opposite transcriptional effects to a common sequence motif in thyroid hormone and estrogen response elements | Q43679715 | ||
The effect of sodium butyrate on histone modification | Q44252246 | ||
dMi-2, a hunchback-interacting protein that functions in polycomb repression | Q47070751 | ||
The histone deacetylase RPD3 counteracts genomic silencing in Drosophila and yeast | Q47072158 | ||
Xenopus HDm, a maternally expressed histone deacetylase, belongs to an ancient family of acetyl-metabolizing enzymes. | Q47776481 | ||
Molecular cloning of Drosophila melanogaster cDNAs that encode a novel histone deacetylase dHDAC3. | Q48001329 | ||
Identification of maize histone deacetylase HD2 as an acidic nucleolar phosphoprotein | Q48047444 | ||
Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression | Q48081415 | ||
Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs | Q48289947 | ||
Role of histone deacetylases in acute leukemia | Q49968588 | ||
The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F | Q52162406 | ||
DNA methylation represses transcription in vivo. | Q52176469 | ||
pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. | Q54048106 | ||
Mechanism of transcriptional repression of E2F by the retinoblastoma tumor suppressor protein. | Q54102655 | ||
Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. | Q54147247 | ||
A growing coactivator network | Q59080836 | ||
P433 | issue | 1 | |
P304 | page(s) | 1-16 | |
P577 | publication date | 2000-07-01 | |
P1433 | published in | Journal of Cellular Physiology | Q1524270 |
P1476 | title | Histone deacetylases, transcriptional control, and cancer | |
P478 | volume | 184 |
Q49804873 | A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas |
Q44325815 | A maize histone deacetylase and retinoblastoma-related protein physically interact and cooperate in repressing gene transcription. |
Q37355387 | A novel domain in histone deacetylase 1 and 2 mediates repression of cartilage-specific genes in human chondrocytes |
Q33732128 | A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors |
Q30464276 | AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas |
Q40694067 | Acetylation inactivates the transcriptional repressor BCL6. |
Q36346870 | Acetylation of HDAC1 and degradation of SIRT1 form a positive feedback loop to regulate p53 acetylation during heat-shock stress |
Q36418796 | Acetylation of histone deacetylase 1 regulates NuRD corepressor complex activity |
Q41553016 | Acetylation- and Methylation-Related Epigenetic Proteins in the Context of Their Targets |
Q59530720 | Acetyltransferase machinery conserved in p300/CBP-family proteins |
Q28576621 | Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor |
Q39677863 | Activation of the mouse histone deacetylase 1 gene by cooperative histone phosphorylation and acetylation |
Q28727541 | Alcohol-induced serotonergic modulation: the role of histone deacetylases |
Q28190777 | Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation |
Q28504879 | Alternate activation of two divergently transcribed mouse genes from a bidirectional promoter is linked to changes in histone modification |
Q34478447 | An Emerging Role for Epigenetic Dysregulation in Arsenic Toxicity and Carcinogenesis |
Q34627182 | An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers |
Q38588663 | Analysis of class I and II histone deacetylase gene expression in human leukemia |
Q40520464 | Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma |
Q41857738 | Anti-Cancer Effect of IN-2001 in MDA-MB-231 Human Breast Cancer |
Q40183784 | Anticancer activities of trichostatin A on maligant lymphoid cells |
Q40236236 | Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer |
Q44700424 | Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades |
Q36908423 | Arabidopsis histone deacetylase 6: a green link to RNA silencing |
Q24519076 | Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors |
Q39887718 | Autoregulation of mouse histone deacetylase 1 expression |
Q34290292 | Avian erythroleukemia: a model for corepressor function in cancer |
Q57243237 | BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis |
Q35828737 | Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease |
Q40490988 | Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A. |
Q33744679 | CDKN1C negatively regulates RNA polymerase II C-terminal domain phosphorylation in an E2F1-dependent manner |
Q28185290 | Ca2+ and BMP-6 signaling regulate E2F during epidermal keratinocyte differentiation |
Q43813890 | Cancer risk in people with epilepsy using valproate-sodium |
Q45740174 | Characterization of intercellular adhesion molecule-1 regulation by Epstein-Barr virus-encoded latent membrane protein-1 identifies pathways that cooperate with nuclear factor kappa B to activate transcription |
Q24307441 | Che-1 arrests human colon carcinoma cell proliferation by displacing HDAC1 from the p21WAF1/CIP1 promoter |
Q44456255 | Chemical genetic modifier screens: small molecule trichostatin suppressors as probes of intracellular histone and tubulin acetylation |
Q36511855 | Chromatin remodeling in cancer: a gateway to regulate gene transcription |
Q28972554 | Circadian Rhythm Disruption in Cancer Biology |
Q80101417 | Class I HDAC SNP analysis in healthy donors compared to AML patients |
Q33724483 | Class II histone deacetylases: from sequence to function, regulation, and clinical implication |
Q92899164 | Clinical Role of Epigenetics and Network Analysis in Eye Diseases: A Translational Science Review |
Q24294179 | Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family |
Q46694039 | Co-treatment of suberoylanilide hydroxamic acid and mitomycin-C induces the apoptosis of rabbit tenon's capsule fibroblast and improves the outcome of glaucoma filtration surgery |
Q35097666 | Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression |
Q42970415 | Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells |
Q34405458 | Common themes in the pathogenesis of acute myeloid leukemia |
Q40039538 | Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate |
Q39404006 | Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells |
Q46118788 | Curcumin-induced histone acetylation in malignant hematologic cells |
Q35971808 | Current knowledge on pancreatic cancer |
Q38354150 | Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. |
Q34528043 | Deacetylase enzymes: biological functions and the use of small-molecule inhibitors |
Q40589176 | Deacetylase recruitment by the C/H3 domain of the acetyltransferase p300. |
Q82270448 | Deacetylation of cortactin by SIRT1 promotes cell migration |
Q46236723 | Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis. |
Q44313511 | Decreased syndecan-2 expression correlates with trichostatin-A induced-morphological changes and reduced tumorigenic activity in colon carcinoma cells |
Q40106235 | Dephosphorylation and caspase processing generate distinct nuclear pools of histone deacetylase 4. |
Q46383982 | Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts |
Q38973120 | Design and synthesis of mono and bicyclic tetrapeptides thioester as potent inhibitor of histone deacetylases |
Q35599579 | Differential Requirement of Histone Acetylase and Deacetylase Activities for IRF5-Mediated Proinflammatory Cytokine Expression |
Q36179533 | Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance? |
Q41876624 | Direct hepatic differentiation of mouse embryonic stem cells induced by valproic acid and cytokines. |
Q36303956 | Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid |
Q39159726 | Dual-acting histone deacetylase-topoisomerase I inhibitors. |
Q95728272 | Effect of DNA Methyltransferase in Comparison to and in Combination with Histone Deacetylase Inhibitors on Hepatocellular Carcinoma HepG2 Cell Line |
Q92462735 | Effect of Sodium Butyrate on LHX1 mRNA Expression as a Transcription Factor of HDAC8 in Human Colorectal Cancer Cell Lines |
Q34583094 | Effects and mechanisms of silibinin on human hepatoma cell lines |
Q40358550 | Effects of sodium phenylbutyrate on differentiation and induction of the P21WAF1/CIP1 anti-oncogene in human liver carcinoma cell lines |
Q37810272 | Emerging role of epigenetic therapies in cutaneous T-cell lymphomas. |
Q36700778 | Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells |
Q28397621 | Environmental chemical exposures and human epigenetics |
Q24292197 | Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR |
Q57570317 | Epigenetic Mechanisms in Cancer Formation and Progression |
Q90470355 | Epigenetic Regulation of MDR1 and BCRP Transporters by HDAC Inhibition |
Q37448564 | Epigenetic mechanisms facilitating oligodendrocyte development, maturation, and aging |
Q37962589 | Epigenetic regulation of HIV-1 transcription |
Q34160419 | Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines |
Q38820193 | Epigenetic regulation of human retinoblastoma |
Q36970179 | Epigenetic regulation of normal and malignant hematopoiesis |
Q37841191 | Epigenetic silencing of tumor suppressor genes in pancreatic cancer |
Q37307226 | Epigenetic therapy of leukemia: An update |
Q26744080 | Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies |
Q37673993 | Erasers of histone acetylation: the histone deacetylase enzymes |
Q34088777 | Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression |
Q38350437 | Expression profile and cellular localization of maize Rpd3-type histone deacetylases during plant development |
Q35237503 | Extracellular molecules involved in cancer cell invasion |
Q24291819 | FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity |
Q44914263 | Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2. |
Q37285451 | Flow-induced HDAC1 phosphorylation and nuclear export in angiogenic sprouting. |
Q39177415 | Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells |
Q40629817 | Functional interplay between modulation of histone deacetylase activity and its regulatory role in G2–M transition |
Q34325633 | Gamma interferon triggers interaction between ICSBP (IRF-8) and TEL, recruiting the histone deacetylase HDAC3 to the interferon-responsive element |
Q36218363 | Gcn5 is required for PU.1-dependent IL-9 induction in Th9 cells. |
Q34828049 | Genome-wide screening for genes associated with valproic acid sensitivity in fission yeast |
Q24310435 | Gfi-1 attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase proteins, and represses transcription using a TSA-sensitive mechanism |
Q37332877 | Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma |
Q39380154 | Glucose and nitrogen regulate the switch from histone deacetylation to acetylation for expression of early meiosis-specific genes in budding yeast |
Q43136823 | Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 modulate beta-cell chromatin structure |
Q28240437 | HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention |
Q40273081 | HDAC inhibition is associated to valproic acid induction of early megakaryocytic markers |
Q36535226 | HDAC inhibitors stimulate viral transcription by multiple mechanisms |
Q35930962 | HDAC1 and HDAC2 are differentially expressed in endometriosis. |
Q33407184 | HDAC3 as a molecular chaperone for shuttling phosphorylated TR2 to PML: a novel deacetylase activity-independent function of HDAC3. |
Q28578773 | HDAC4 and PCAF bind to cardiac sarcomeres and play a role in regulating myofilament contractile activity |
Q34399444 | Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies |
Q34193936 | Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code |
Q37382318 | Histone H4 N-terminal acetylation in Kasumi-1 cells treated with depsipeptide determined by acetic acid-urea polyacrylamide gel electrophoresis, amino acid coded mass tagging, and mass spectrometry |
Q34138023 | Histone acetylation: lessons from the plant kingdom |
Q34956099 | Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation |
Q37201244 | Histone deacetylase (HDAC) 10 suppresses cervical cancer metastasis through inhibition of matrix metalloproteinase (MMP) 2 and 9 expression |
Q36017473 | Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1 |
Q35439528 | Histone deacetylase 1 and 3 regulate the mesodermal lineage commitment of mouse embryonic stem cells |
Q43950174 | Histone deacetylase 1 inactivation by an adenovirus early gene product. |
Q24673033 | Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras |
Q24550857 | Histone deacetylase 4 possesses intrinsic nuclear import and export signals |
Q34336927 | Histone deacetylase as a therapeutic target |
Q34795203 | Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases |
Q34109688 | Histone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancers |
Q43844100 | Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis |
Q40082894 | Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells |
Q39957667 | Histone deacetylase inhibitor-induced cellular apoptosis involves stanniocalcin-1 activation. |
Q80489191 | Histone deacetylase inhibitors |
Q36645808 | Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents |
Q38595978 | Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies |
Q36599926 | Histone deacetylase inhibitors as therapeutics for polyglutamine disorders |
Q35609717 | Histone deacetylase inhibitors in clinical development |
Q37118947 | Histone deacetylase inhibitors in lymphoma and solid malignancies |
Q39752287 | Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy |
Q36959997 | Histone deacetylase inhibitors modify pancreatic cell fate determination and amplify endocrine progenitors |
Q40341141 | Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma |
Q40402559 | Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2. |
Q37089077 | Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells |
Q38055210 | Histone deacetylase inhibitors: a patent review (2009 - 2011). |
Q35011880 | Histone deacetylase inhibitors: from target to clinical trials |
Q24290482 | Histone deacetylase interacts directly with DNA topoisomerase II |
Q38655401 | Histone deacetylase-mediated morphological transition in Candida albicans |
Q24535587 | Histone deacetylases (HDACs): characterization of the classical HDAC family |
Q34570082 | Histone deacetylases and cancer: causes and therapies |
Q38019133 | Histone deacetylases in viral infections |
Q51023885 | Histone deacetylases: purification of the enzymes, substrates, and assay conditions. |
Q37023918 | Histone deacetylases: target enzymes for cancer therapy |
Q36510514 | Histone deacetylation as a target for radiosensitization |
Q34322087 | Histone modification enzymes: novel targets for cancer drugs |
Q34743301 | Histone-deacetylase inhibitors: novel drugs for the treatment of cancer |
Q24533247 | Human telomerase and its regulation |
Q33212678 | Identification and analysis of tumour-associated antigens in hepatocellular carcinoma |
Q24292353 | Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain |
Q40569139 | Identification of genes that are regulated transcriptionally by Myc in childhood tumors |
Q28206130 | Identification of histone deacetylase-3 domains that interact with the orphan nuclear receptor TR2 |
Q39030316 | Identification of proteins related to epigenetic regulation in the malignant transformation of aberrant karyotypic human embryonic stem cells by quantitative proteomics |
Q22330788 | Identification of the ankyrin repeat proteins ANKRA and RFXANK as novel partners of class IIa histone deacetylases |
Q37733359 | Identification of type-specific anticancer histone deacetylase inhibitors: road to success |
Q36256046 | Immunoexpression of HDAC1, HDAC2, and HAT1 in actinic cheilitis and lip squamous cell carcinoma. |
Q41881419 | Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. |
Q40693659 | Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells |
Q91809711 | Induction of Apoptosis and Autophagy in Breast Cancer Cells by a Novel HDAC8 Inhibitor |
Q81308372 | Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1 |
Q39686347 | Inhibition of polyomavirus ori-dependent DNA replication by mSin3B |
Q39644032 | Inhibitors selective for HDAC6 in enzymes and cells |
Q34371357 | Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program |
Q24291719 | Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles |
Q34463350 | Interaction of histone acetylases and deacetylases in vivo |
Q34736677 | Interview with the retinoblastoma family members: do they help each other? |
Q43773523 | Involvement of histone deacetylase at two distinct steps in gene regulation during intestinal development in Xenopus laevis |
Q38262101 | JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis |
Q35150732 | Loss of Sin3/Rpd3 histone deacetylase restores the DNA damage response in checkpoint-deficient strains of Saccharomyces cerevisiae |
Q39026671 | Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC. |
Q24295092 | MRGX Is a Novel Transcriptional Regulator That Exhibits Activation or Repression of the B-myb Promoter in a Cell Type-dependent Manner |
Q38886365 | Marine Actinomycetes as potential source for histone deacetylase inhibitors and epigenetic modulation |
Q35882554 | Mitochondrial DNA variants can mediate methylation status of inflammation, angiogenesis and signaling genes. |
Q28176911 | Modulation of YY1 activity by SAP30 |
Q37708543 | Modulation of cell cycle regulators by HDACs |
Q24301083 | Modulation of p120E4F transcriptional activity by the Gam1 adenoviral early protein |
Q58805430 | Molecular testing in the diagnosis of differentiated thyroid carcinomas |
Q36973287 | Multiple endocrine neoplasia type 1 (MEN1) as a cancer predisposition syndrome: clues into the mechanisms of MEN1-related carcinogenesis |
Q38878493 | NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells |
Q37480036 | NF-kappaB regulation: the nuclear response |
Q24672508 | Negative and positive regulation of gene expression by mouse histone deacetylase 1 |
Q37238757 | New developments in the diagnosis and treatment of thyroid cancer |
Q37784821 | Nitric Oxide Signaling and Nitrosative Stress in Neurons: Role forS-Nitrosylation |
Q37691759 | Novel agents for B-cell non-Hodgkin lymphoma: science and the promise |
Q37872269 | Novel molecular targeted therapies for refractory thyroid cancer |
Q42175822 | Nuclear Smad7 Overexpressed in Mesenchymal Cells Acts as a Transcriptional Corepressor by Interacting with HDAC-1 and E2F to Regulate Cell Cycle |
Q34448240 | Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation |
Q36822431 | Oxidative stress and steroid resistance in asthma and COPD: pharmacological manipulation of HDAC-2 as a therapeutic strategy |
Q37992104 | Panobinostat for the treatment of multiple myeloma |
Q38269612 | Panobinostat: a review of trial results and future prospects in multiple myeloma |
Q34130676 | Paradigms of growth control: relation to Cdk activation |
Q37350321 | Parameterization of aromatic azido groups: application as photoaffinity probes in molecular dynamics studies |
Q38113568 | Peripheral T-cell lymphomas: a review of current approaches and hopes for the future |
Q43269070 | Peroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells |
Q33857133 | Phospho-acetylation of histone H3 in the amygdala after acute lithium chloride. |
Q24538513 | Physical and functional interactions of histone deacetylase 3 with TFII-I family proteins and PIASxbeta |
Q28088517 | Post-translational modifications regulate class IIa histone deacetylase (HDAC) function in health and disease |
Q42805877 | Pro-proliferative function of the long isoform of PML-RARalpha involved in acute promyelocytic leukemia |
Q34271581 | Protein modules that manipulate histone tails for chromatin regulation |
Q33411313 | RTA promoter demethylation and histone acetylation regulation of murine gammaherpesvirus 68 reactivation |
Q40241396 | Recruitment of histone deacetylase 4 by transcription factors represses interleukin-5 transcription |
Q39363633 | Regulation of a novel androgen receptor target gene, the cyclin B1 gene, through androgen-dependent E2F family member switching |
Q34498083 | Regulation of gene expression by the proto-oncogene BCL-6. |
Q44039963 | Regulation of histone deacetylase 2 by protein kinase CK2. |
Q24550859 | Regulation of transcription factor YY1 by acetylation and deacetylation |
Q35939577 | Relevance of systems biological approach in the differential diagnosis of invasive lobular carcinoma & invasive ductal carcinoma |
Q24680884 | Repression of E2F1-mediated transcription by the ErbB3 binding protein Ebp1 involves histone deacetylases |
Q34265747 | Ritonavir acts synergistically with panobinostat to enhance histone acetylation and inhibit renal cancer growth |
Q35948150 | Role for histone deacetylase 1 in human tumor cell proliferation |
Q47391539 | Role of TCTP for Cellular Differentiation and Cancer Therapy. |
Q24537037 | Role of the Sin3-histone deacetylase complex in growth regulation by the candidate tumor suppressor p33(ING1). |
Q40519227 | Role of the tetradecapeptide repeat domain of human histone deacetylase 6 in cytoplasmic retention. |
Q33697130 | Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors |
Q35946026 | Roles of dynamic and reversible histone acetylation in plant development and polyploidy |
Q37172534 | Roles of zinc and zinc signaling in immunity: zinc as an intracellular signaling molecule |
Q33408509 | Romidepsin for the treatment of T-cell lymphomas |
Q58120159 | SIRT1 rs3758391 polymorphism and risk of diffuse large B cell lymphoma in a Chinese population |
Q35096677 | STAT1 signaling is not regulated by a phosphorylation-acetylation switch |
Q42816242 | SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities |
Q43540936 | Sex-dependent regulation by dexamethasone of murine hydroxysteroid sulfotransferase gene expression |
Q28468627 | Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway |
Q38168292 | Sirtuins and cancer: new insights and cell signaling |
Q36071880 | Solid tumor differentiation therapy - is it possible? |
Q45146761 | Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung |
Q24311550 | Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain |
Q34459769 | Structure of histone deacetylases: insights into substrate recognition and catalysis |
Q53527364 | Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells. |
Q53665023 | Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC). |
Q90381364 | Suppressing migration and invasion of H1299 lung cancer cells by honokiol through disrupting expression of an HDAC6-mediated matrix metalloproteinase 9 |
Q43139883 | Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase |
Q25255820 | TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters |
Q42827376 | TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3. |
Q37307340 | TRAIL gene therapy: from preclinical development to clinical application |
Q36529933 | Targeting epigenetic abnormalities with histone deacetylase inhibitors |
Q34438734 | Tax relieves transcriptional repression by promoting histone deacetylase 1 release from the human T-cell leukemia virus type 1 long terminal repeat. |
Q24535726 | The FK506-binding protein 25 functionally associates with histone deacetylases and with transcription factor YY1. |
Q34441108 | The SIN3/RPD3 deacetylase complex is essential for G(2) phase cell cycle progression and regulation of SMRTER corepressor levels |
Q38941593 | The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer |
Q34387654 | The deacetylase HDAC1 negatively regulates the cardiovascular transcription factor Krüppel-like factor 5 through direct interaction. |
Q57574782 | The emerging role of class II histone deacetylases |
Q24294822 | The functional interactome landscape of the human histone deacetylase family |
Q46866555 | The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma |
Q24294872 | The histone deacetylase 9 gene encodes multiple protein isoforms |
Q24554277 | The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain |
Q28201932 | The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity |
Q40501718 | The pancreatic duodenal homeobox-1 protein (Pdx-1) interacts with histone deacetylases Hdac-1 and Hdac-2 on low levels of glucose |
Q24656159 | The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer |
Q37333510 | The role of histone deacetylases in prostate cancer. |
Q36822457 | The therapeutic uses of chromatin-modifying agents |
Q28285366 | The transcriptional corepressor, PELP1, recruits HDAC2 and masks histones using two separate domains |
Q100395393 | Transcription tipping points for T follicular helper cell and T-helper 1 cell fate commitment |
Q24292875 | Transcriptional regulation by the repressor of estrogen receptor activity via recruitment of histone deacetylases |
Q37210234 | Trichostatin A Enhances the Apoptotic Potential of Palladium Nanoparticles in Human Cervical Cancer Cells |
Q34480485 | Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells |
Q53217325 | Trichostatin a promotes cardiomyocyte differentiation of rat mesenchymal stem cells after 5-azacytidine induction or during coculture with neonatal cardiomyocytes via a mechanism independent of histone deacetylase inhibition. |
Q40642091 | Triggering of p73-dependent apoptosis in osteosarcoma is under the control of E2Fs-pRb2/p130 complexes |
Q36610835 | Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial |
Q33998266 | Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells |
Q39570650 | Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. |
Q35939690 | Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects |
Q57007087 | pRb2/p130 and p107 control cell growth by multiple strategies and in association with different compartments within the nucleus |
Q42515747 | v-Src-mediated down-regulation of SSeCKS metastasis suppressor gene promoter by the recruitment of HDAC1 into a USF1-Sp1-Sp3 complex |
Search more.